Incidence of local recurrence in relation to radiotherapy and trastuzumab in early Her2 positive breast cancer

被引：0
|
作者：
Traa, F. [1 ]
Vane, M. [1 ]
Van Roozendaal, L. [2 ]
Heuts, E. [1 ]
Siesling, S. [3 ]
Moossdorff, M. [2 ]
Smidt, M. [1 ]
机构：
[1] Maastricht Univ, Med Ctr, Surg, Maastricht, Netherlands
[2] Zuyderland Med Ctr, Surg, Heerlen, Netherlands
[3] Univ Twente, MIRA Inst Biomed Technol & Tech Med, Hlth Technol & Serv Res, Enschede, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2018年 / 92卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
368 (PB-16
引用
收藏
页码：S104 / S105
页数：2
相关论文
共 50 条
  • [31] ADJUVANT TC (DOCETAXEL/CYCLOPHOSPHAMIDE)-HER (TRASTUZUMAB) (TC-HER) IN HER2 POSITIVE BREAST CANCER
    Hara, F.
    Kiyoto, S.
    Takahashi, M.
    Takabatake, D.
    Takashima, S.
    Aogi, K.
    Ohsumi, S.
    BREAST, 2013, 22 : S87 - S87
  • [32] Evaluation of early cardiotoxicity in HER2-positive breast cancer patients receiving radiotherapy and concurrent trastuzumab
    Aslan, Dicle
    Ozoner, Sadik
    Inanc, Mevlude
    Yildiz, Oguz Galip
    Inanc, Mehmet Tugrul
    IRISH JOURNAL OF MEDICAL SCIENCE, 2025, 194 (01) : 7 - 18
  • [33] Role of trastuzumab in patients with brain metastases from Her2 positive breast cancer
    Bulut, Nilufer
    Harputluoglu, Hakan
    Dizdar, Omer
    Altundag, Kadri
    JOURNAL OF NEURO-ONCOLOGY, 2008, 86 (02) : 241 - 241
  • [34] Outcome of HER2 positive breast cancer by PR expression since the introduction of trastuzumab
    Van Asten, K.
    Jongen, L.
    Beuselinck, B.
    Laenen, A.
    Wildiers, H.
    Poppe, A.
    Floriss, G.
    Christiaens, M.
    Neven, P.
    BREAST, 2015, 24 : S119 - S119
  • [35] Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.
    Bayo, J
    Mayordomo, JI
    Sanchez-Rovira, P
    Perez-Carrion, R
    Illaramendi, J
    Flores, EG
    Bueno, JMG
    Vazquez, MR
    Crespo, C
    Palomo, AG
    Huelva, HJRJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 67S - 67S
  • [36] Clinical outcome of treatment without trastuzumab in HER2 positive breast cancer patients
    Aye, T. T.
    Mon, S.
    Khine, M.
    Sein, N.
    Thant, N. M.
    Win, A. K.
    Aung, E. P. P.
    Hnin, P. T.
    ANNALS OF ONCOLOGY, 2019, 30
  • [37] TRASTUZUMAB EMTANSINE FOR HER2 POSITIVE BREAST CANCER PATIENTS: AN UPDATED SYSTEMATIC REVIEW
    Valle, P. M.
    Mosegui, G. B.
    Vianna, C. M.
    Araujo, R. L.
    Felicissimo, T.
    Lima, I. J.
    VALUE IN HEALTH, 2015, 18 (07) : A816 - A816
  • [38] Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity
    Ajgal, Z.
    de Percin, S.
    Dieras, V.
    Pierga, J. Y.
    Campana, F.
    Fourquet, A.
    Kirova, Y. M.
    CANCER RADIOTHERAPIE, 2017, 21 (02): : 114 - 118
  • [39] Modelling hypersensitivity to trastuzumab defines biomarkers of response in HER2 positive breast cancer
    Laura Díaz-Gil
    Fara Brasó-Maristany
    Claudriana Locatelli
    Ariana Centa
    Balász Győrffy
    Alberto Ocaña
    Aleix Prat
    Atanasio Pandiella
    Journal of Experimental & Clinical Cancer Research, 40
  • [40] Understanding Trastuzumab Resistance in HER2 Positive Breast Cancer and Further Therapeutic Options
    Bae, Sangmee
    Hurvitz, Sara
    CURRENT CANCER THERAPY REVIEWS, 2015, 11 (04) : 269 - 291
12345